Evotec SE (NASDAQ:EVO) Q4 2021 Earnings Conference Call April 12, 2022 8:00 AM ET Company Participants Werner Lanthaler - Chairman and Chief Executive Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer Enno Spillner - Chief Financial Officer Conference Call Participants James Quigley - Morgan Stanley Joseph Hedden - Rx Securities Falko Friedrichs - Deutsche Bank Igor Kim - Berenberg Michael Ryskin - Bank of America Zoe Karamanoli - RBC Capital Markets Operator Dear la ...

Financial Data and Key Metrics Changes - The company reported a 17% increase in revenue for H1 2021, with a strong 27% organic growth when adjusted for foreign exchange and portfolio effects [13] - Gross margin decreased to 20.8% from 23% year-on-year, primarily due to the end of the Sanofi subsidy for the Toulouse site [14] - R&D expenses increased by 90% compared to last year, driven by enhancements to multiple platforms and the co-owned pipeline [14] - Net income for H1 2021 amounted to €111.9 million, benefiting from a positive one-off effect from the fair value upgrade of the Exscientia/Evo equity engagement [17] Business Line Data and Key Metrics Changes - Execute revenues grew by 18% year-to-date, driven by increasing demand for integrated offerings and a strong base business [21] - Innovate revenues reached €57.3 million, a 27% increase, reflecting high demand for precision medicine and new partnerships [22] - Innovate's adjusted EBITDA was negative at €15.7 million, primarily due to increased R&D and SG&A investments [23] Market Data and Key Metrics Changes - The company experienced a negative currency effect of €11.5 million due to a weakened US dollar against the euro [25] - The order books are at record levels, indicating strong long-term demand across all offerings [11] Company Strategy and Development Direction - The company aims to create the largest royalty pool in the industry by co-owning valuable assets, with a focus on long-term value creation [44] - The J.POD initiative is a strategic response to the anticipated global shortage of biologics capacity, with plans for expansion in both the US and Europe [42][71] - The company is committed to integrating AI and machine learning across various modalities, enhancing productivity and precision in drug discovery [61][64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the second half of 2021, anticipating substantial additional income from milestones originally expected in Q2 [20] - The company is closely monitoring inflation and input costs but currently does not expect immediate impacts due to strong stock levels and increased buying power [81] - The company confirmed its guidance for 2021, expecting strong news flow and a top line of €550 million to €570 million [57] Other Important Information - The company is pursuing a dual listing on NASDAQ to increase engagement with US institutional investors and support growth initiatives [35][86] - The company is actively involved in social responsibility initiatives, particularly in response to the COVID-19 pandemic, aiming to improve access to therapeutics globally [50][101] Q&A Session Summary Question: Trends in AI-based drug discovery and Evotec's positioning - The company applies machine learning across various modalities, leveraging data from top pharma and biotech partners to enhance productivity [61][62] Question: Cold Spring Harbor lab collaboration focus - The collaboration aims to translate ideas across all modalities, not limited to biologics [66] Question: Timeline for J.POD 1 manufacturing capacity - Full capacity for the first two trains is expected within the next 24 months, driven by business demand [70] Question: Guidance on adjusted EBITDA - The company is optimistic about the second half due to expected data points and novel transactions, despite the inherent volatility of milestone payments [76][78] Question: Update on Phase III compound with JingXin - JingXin has accelerated recruitment for their clinical trial, and the company remains optimistic about their progress [80] Question: NASDAQ listing expectations - The dual listing aims to increase visibility and attract US-based investors, with no urgent financing pressure [86][87] Question: Protein degradation agreement with BMS - The company is actively involved in protein degradation and has expanded its partnership with BMS into new disease areas [95][96]

Financial Performance H1 2021 - Group revenues increased by 17% to €2713 million (H1 2020: €2310 million), with organic growth at a record level of 27%[11] - Adjusted Group EBITDA decreased by 23% to €362 million (H1 2020: €473 million), mainly due to planned capacity build-up ahead of the imminent production start of J·POD® 1 US, like-for-like growth was 13%[11] - Expenses for unpartnered R&D increased by 29% to €278 million (H1 2020: €216 million)[11] - Net income increased significantly by over 100% to €1127 million (H1 2020: €73 million), benefiting from the fair value adjustment of EVO equity investment Exscientia[18] - Base revenues increased by 17% or €381 million to €2613 million, with Just – Evotec Biologics adding revenues of €230 million, an increase of 44%[20] Guidance and Outlook - The company confirmed its 2021 outlook, projecting Group revenues of €550-570 million (2020: €5009 million) and adjusted Group EBITDA of €105-120 million (2020: €1066 million)[11] - Unpartnered R&D expenses are expected to be €50-60 million (2020: €464 million)[11] - Action Plan 2025 targets were confirmed, aiming for revenues > €1000 million, adjusted EBITDA ≥ €300 million, and unpartnered R&D > €100 million[11] Strategic Developments - The acquisition of the Verona site from GlaxoSmithKline SpA was completed, now named "Campus Levi-Montalcini"[10, 35, 37] - A significant extension of the BMS Oncology protein degradation partnership was achieved ahead of term, along with a new protein degradation collaboration in an undisclosed therapeutic area also signed with BMS[10, 46] - J·POD® 1 US in Redmond is opening on August 18th, and construction of J·POD® 2 EU is set to start in Q4 2021[10] - The company submitted a registration statement for a proposed offering of American Depositary Shares (after period-end)[10]

Financial Data and Key Metrics Changes - Q1 2021 revenue increased by 11%, with a 17% gain when adjusted for foreign exchange effects [13] - Gross margin was 23.1%, lower than the previous year due to the fadeout of the Sanofi subsidy and lower milestone achievements [14] - Adjusted EBITDA for Q1 2021 was €21.1 million, aligning with expectations [17] - Net income amounted to €52.7 million, benefiting from a one-off effect related to the fair value adjustment of Exscientia shares [17] Business Line Data and Key Metrics Changes - Execute revenues increased to €137 million from €118 million in Q1 2020, driven by demand for integrated offerings [20] - Innovate Q1 revenues reached €28.2 million, a 21% increase year-over-year, reflecting higher demand for precision medicine [22] - The gross margin for Execute was 21.4%, down from 29.3% the previous year, primarily due to the absence of Sanofi payments [21] Market Data and Key Metrics Changes - The overall sales development was negatively impacted by the end of Sanofi Toulouse payments and adverse foreign exchange effects, with a currency effect of minus €6 million [24] - The company reported a strong organic growth of 26% in the base business, indicating solid revenue quality from sustainable repeat business [23] Company Strategy and Development Direction - The company introduced an updated business model called "Action Plan 2025," focusing on data-driven R&D and achieving leadership in data and science [6][7] - The strategy emphasizes building a co-owned pipeline and leveraging data for drug discovery, aiming to create significant value through innovation [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2021 goals despite ongoing COVID-19 challenges, with a strong long-term outlook [5] - The company anticipates increased activity in its co-owned pipeline as clinical centers reopen, expecting positive momentum in the second half of the year [30] - The long-term plan includes expected group revenues between €560 million and €570 million and EBITDA between €105 million and €120 million for 2021 [41] Other Important Information - Total liquidity decreased to €460.6 million, primarily due to expected capital expenditures for growth projects [27] - The company is committed to ESG initiatives, integrating these topics into employee goals and organizational strategies [39][40] Q&A Session Questions and Answers Question: Details on the OxVax collaboration - The company views itself as an operational synergy-seeking investor in the OxVax project, leveraging its iPSC platform [45] Question: Clarification on the collaboration with BMS - The partnership with BMS focuses on exploiting protein degradation strategies, but specific details cannot be disclosed [46] Question: Update on EVT801 and expectations from Kazia Therapeutics - The clinical entry for EVT801 is expected by the end of 2021 or early 2022, with Kazia showing strong scientific insight [47] Question: Extrapolation of operating income for the year - The operating income is expected to remain stable, with slight increases in tax credits and SG&A as the organization grows [55] Question: Update on the beta cell project and monetization of data - The CureBeta initiative is progressing well, with discussions ongoing with pharma and venture partners for potential licensing or company formation [60] - The company is already monetizing data through partnerships, such as with Novo Nordisk, leveraging its NURTuRE database [61] Question: Update on iPSC candidates entering the clinic - The first iPSC-derived novel target is expected to enter the clinic in the second half of 2021, with positive progress reported [86]

H PECCAACUNGVERJIVIN Accelerating on the data- driven Autobahn to Cures 【】【】【【】【 Evotec SE, First quarter 2021 results, 11 May 2021 Cautionary statement regarding forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate", "believe", "could", "estimate", "expect", "goa ...

| --- | --- | |-------------------------------------------------------------------------------------------|-------| | | | | | | | The data-driven R&D Autobahn to Cures Evotec SE, Full-year 2020 results, 25 March 2021 | | and and the see and a be a comment of the subseries of Forward looking statement | --- | |--------------------------------------------------------------------------------------------| | | | Information set forth in this presentation contains forward-looking statements, which | | involve a n ...

Evotec SE (OTCPK:EVOTF) Q4 2020 Earnings Conference Call March 25, 2021 9:00 AM ET Company Participants Werner Lanthaler - CEO Enno Spillner - CFO Cord Dohrmann - Chief Scientific Officer Craig Johnstone - COO Conference Call Participants Joseph Hedden - Rx Securities Limited Falko Friedrichs - Deutsche Bank Charles Weston - RBC Capital Markets Naresh Chouhan - Intrinsic Health Advisors Victoria English - MedNous Mohamad Vaseghi - Frankfurt Main Research Christian Ehmann - Warburg Research Operator Dear lad ...

Evotec SE (OTCPK:EVOTF) Q3 2020 Earnings Conference Call November 12, 2020 8:00 AM ET Company Participants Werner Lanthaler - CEO Enno Spillner - CFO Craig Johnstone - COO Cord Dohrmann - Chief Scientific Officer Conference Call Participants Igor Kim - Bankhaus Lampe Nick Nieland - Citigroup Charles Weston - RBC Capital Markets Bruno Bulic - Baader-Helvea Joseph Hedden - Rx Securities Limited Naresh Chouhan - Intrinsic Health Advisors Kieron Banerjee - goetzpartners securities Victoria English - Evernow Pub ...

Financial Performance (9M 2020) - Group revenues increased by 12% to €360.4 million compared to €321.4 million in 9M 2019 [11] - Like-for-like growth of the base business, adjusted for portfolio and FX effects, was up by 19% [11] - Adjusted Group EBITDA was €76.9 million, compared to €93.2 million in 9M 2019, but showed a strong upswing in Q3 [11] - Increased investment in unpartnered R&D expenses to €33.4 million, up from €25.7 million in 9M 2019 [11] - R&D expenses reached €46.1 million, a 12% increase from €41.3 million in 9M 2019 [17] Q3 2020 Highlights - Revenue growth was driven by strong performance in the base business, with improved revenues from milestones, upfronts, and licenses [21] - Revenues from contracts with customers reached €129.4 million in Q3 2020, compared to €114.3 million in Q3 2019 [21] Guidance 2020 - Total Group revenues are expected to range from €440 million to €480 million, based on constant 2019 exchange rates [11, 48] - Adjusted Group EBITDA is expected to be in the range of €100 million to €120 million [11, 48] - Unpartnered Group R&D expenses are projected to be approximately €45 million [11, 48] Strategic Investments and Partnerships - Mubadala Investment Company made a €200 million investment, translating into 5.6% of the total new number of 163.5 million Evotec shares [15]

U MECCABCHNEVCKJIDTO Evotec Partnered Drug Discovery and Development Evotec SE, Company Presentation, H.C. Wainwright 22nd Annual Global Investment Conference, 14 September 2020 Forward-looking statement Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor g ...